Processa Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Processa Pharmaceuticals, Inc. (PCSA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $238.92 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-29
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $238.92K.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $17.77K, a 93.94% decline from fiscal 2019.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $293.20K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $238.92K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $238.92K 10-Q · filed 2023-11-13 | |||
| 2020-12-31 | $17.77K 10-K · filed 2022-03-30 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $293.20K 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $293.20K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $293.20K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $293.20K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |